Explore 3 Stock Ideas & Industry Insights Download Free Report

Entera Bio Ltd

Company price
3.05 USD 0.03 ( 0.99%)
Last update at 2026-11-17T14:55:00Z
VOLUME
13556
Market Cap
495.19M

Momentum Score

…

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.04
Low
3.10
High
52 Week Price Range
0.91
Low
4.20
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Entera Bio Ltd is a clinical-stage biotechnology company developing oral formulations of peptide and protein therapeutics using a proprietary delivery platform. Long-term growth may be driven by positive clinical data, regulatory approvals, and partnerships if oral alternatives gain adoption versus injectables.

Key risks include clinical or regulatory failure, need for continued financing, manufacturing and intellectual property challenges, and strong competition that could hinder commercialization.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.02
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.04
ROE
-138.92%
Net Debt
-6.62M
ROCE
-82.95%
Diluted EPS TTM
-0.35

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -11.44M -9.53M -8.86M -12.93M -12.25M
Net income -11.44M -9.54M -8.89M -13.07M -12.19M
Selling general administrative 5.53M 5.09M 4.43M 7.25M 5.69M
Gross profit -0.03M 0.01M -0.06M 0.03M 0.20M
Reconciled depreciation 0.03M 0.05M 0.06M 0.06M 0.05M
Ebit -11.44M -9.53M -8.86M -13.08M -12.22M
Ebitda -11.41M -9.48M -8.80M -13.02M -12.16M
Depreciation and amortization 0.03M 0.05M 0.06M 0.06M 0.05M
Operating income -11.53M -9.59M -8.94M -13.02M -12.22M
Other operating expenses 11.57M 9.77M 8.94M 13.15M 12.79M
Interest expense - - - 26.00M 0.03M
Tax provision 0.00M 0.01M -0.02M 0.14M -0.06M
Net interest income 0.09M 0.06M 0.05M 0.08M -0.03M
Income tax expense 11.53M 0.01M 0.03M 0.14M -0.06M
Total revenue 0.04M 0.18M 0.01M 0.13M 0.57M
Total operating expenses 11.53M 9.59M 8.88M 13.05M 12.41M
Cost of revenue 0.04M 0.17M 0.06M 0.10M 0.37M
Total other income expense net 0.09M 0.06M 0.08M 0.08M -0.03M
Net income from continuing ops -11.44M -9.54M -9.93M -13.07M -12.19M
Net income applicable to common shares - - - -13.07M -12.19M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 15.99M 9.39M 11.77M 13.13M 25.99M
Other current assets -0.22M 0.19M 0.24M 0.29M 0.25M
Total liab 2.89M 1.31M 1.38M 1.37M 3.42M
Total stockholder equity 13.10M 8.08M 10.39M 11.75M 22.57M
Other current liab 1.52M 0.87M 0.87M -0.13M 2.80M
Common stock 0.00M 0.00M 0.00M - -
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -125.37M -113.93M -104.39M -95.50M -82.43M
Other liab - - - 0.03M 0.14M
Other assets 8.75M - - 0.05M 0.26M
Cash 7.11M 8.66M 11.02M 12.31M 24.89M
Total current liabilities 2.20M 1.18M 1.09M 1.34M 3.16M
Current deferred revenue - - - 0.04M 0.01M
Net debt -6.62M -8.39M -10.63M -12.22M -24.59M
Short term debt 0.23M 0.17M 0.13M 0.09M 0.18M
Short long term debt total 0.49M 0.27M 0.39M 0.09M 0.30M
Other stockholder equity 138.43M 121.97M 114.73M 107.21M 104.95M
Property plant equipment - - - 0.23M 0.40M
Total current assets 7.11M 8.97M 11.26M 12.85M 25.33M
Net tangible assets - - - 11.75M 22.57M
Net receivables 0.22M 0.13M 0.00M 0.54M 0.18M
Inventory - - - -0.29M -
Accounts payable 0.45M 0.13M 0.08M 1.34M 0.17M
Accumulated other comprehensive income 0.04M 0.04M 0.04M 0.04M 0.04M
Non currrent assets other -0.09M 0.01M 0.01M 0.10M 0.05M
Non current assets total 0.13M 0.42M 0.51M 0.28M 0.66M
Capital lease obligations 0.49M 0.27M 0.39M 0.09M 0.30M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.00M -0.01M -0.10M -0.02M
Change to liabilities - - - -0.16M -0.14M
Total cashflows from investing activities -0.11M -0.00M -0.02M -0.10M -0.02M
Total cash from financing activities 13.71M 4.48M 6.04M 0.01M 25.38M
Change to operating activities - - - -1.61M 1.48M
Net income -11.44M -9.54M -8.89M -13.07M -12.19M
Change in cash 6.23M -2.35M -1.29M -12.59M 16.30M
Begin period cash flow 8.74M 11.09M 12.38M 24.96M 8.66M
End period cash flow 14.97M 8.74M 11.09M 12.38M 24.96M
Total cash from operating activities -7.37M -6.82M -7.31M -12.50M -9.06M
Issuance of capital stock 13.44M 3.96M 0.01M 0.00M 21.80M
Depreciation 0.03M 0.05M 0.06M 0.06M 0.05M
Other cashflows from investing activities - - - -0.06M -0.06M
Change to inventory - - - - -0.07M
Change to account receivables 0.13M -0.13M 0.25M -0.06M 0.07M
Other cashflows from financing activities 13.71M 0.52M -0.58M 0.01M 3.58M
Change to netincome - - - 2.34M 1.66M
Capital expenditures 0.11M 0.00M 0.02M 0.05M 0.02M
Change in working capital 1.26M 0.11M -0.20M -1.83M 1.41M
Stock based compensation 2.75M 2.56M 1.69M 2.25M 1.86M
Other non cash items 0.03M -0.01M 1.69M -0.08M 0.02M
Free cash flow -7.48M -6.82M -7.33M -12.55M -9.08M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ENTX
Entera Bio Ltd
0.03
0.99%
3.05 - - 1547.08 67.20 1527.79 -1.52
NVO
Novo Nordisk A/S
-1.21
2.90%
40.40 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-6.15
1.14%
531.64 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
4.70
0.49%
957.10 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Entera Bio Ltd

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.

Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002

972 2 532 7151

20

Name Title Year Born
Ms. Miranda J. Toledano M.B.A. CEO & Director 1977
Dr. Hillel Galitzer M.B.A., Ph.D. Chief Operating Officer 1978
Ms. Dana Yaacov-Garbeli CPA CFO & Principal Financial Officer 1983
Dr. Arthur C. Santora II, M.D., Ph.D. Chief Medical Officer 1951
Ms. Dana Yaacov-Garbeli CPA Chief Financial Officer 1983
Dr. Gregory Burshtein Ph.D. Chief of Research & Development 1977
Dr. Rachel B. Wagman Chief Clinical Advisor NA
Ms. Cherin Smith Executive VP & Head of Clinical Operations NA
Dr. Constantin Itin Ph.D., R.Ph. Head of Biopharmaceutics & Bioanalytics NA
Ms. Michele McDermott MD & EVP of Medical Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…